Please login to the form below

Not currently logged in
Email:
Password:

HCV

This page shows the latest HCV news and features for those working in and with pharma, biotech and healthcare.

Gilead wins European approval for triple hep C combination Vosevi

Gilead wins European approval for triple hep C combination Vosevi

This marks another win for the biopharma as Harvoni is the first DAA chronic HCV treatment to be granted an extension to treat adolescents in the European Union. ... the benefits of our other approved medicines for patients with chronic HCV infection

Latest news

  • Merck & Co pulls out of hepatitis C R&D as market shrinks Merck & Co pulls out of hepatitis C R&D as market shrinks

    This turned out to be an over-confident prediction, with the HCV market already contracting as a result of pricing competition and a shrinking patient pool. ... The new decision comes after it already booked a $2.9bn impairment charge related to the HCV

  • Gilead makes $11.9bn play for CAR-T specialist Kite Gilead makes $11.9bn play for CAR-T specialist Kite

    Gilead's deal comes as it faces a sharp slowdown in sales of its HCV therapies - led by Harvoni (sofosbuvir and ledipasvir) and Sovaldi (sofosbuvir) - which has led investors to call ... makes it Gilead's largest takeover since it bought Pharmasset for

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    Gilead gets OK for three-in-one hep C therapy in US. FDA clears the new product for the most common HCV genotypes. ... Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and

  • Two new hepatitis C therapies fast-tracked in Europe Two new hepatitis C therapies fast-tracked in Europe

    cure for chronic hepatitis C virus (HCV) patients who have failed other regimens. ... The two new drug combinations will enter a rapidly evolving HCV treatment market.

  • Gilead files hepatitis C salvage regimen in US Gilead files hepatitis C salvage regimen in US

    Merck &Co's elbasvir, which currently represent the most effective approach to HCV infection. ... There really isn't much left in terms of unmet medical need [in HCV]," said Gilead chief executive John Milligan.

More from news
Approximately 8 fully matching, plus 119 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    The agreement covers ACH 3102, ACH 3422 and sovaprevir. The intention is to trial a combination of ACH 3102 with a NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    virus (HCV) to help navigate the care system and make the most of new treatments. ... And obviously the NHS saves on downstream costs associated with HCV, such as liver disease and the prospect of liver transplants.

  • Communicating value Communicating value

    We are seeing instances, eg in HCV, where simple affordability, rather than cost effectiveness, is a major factor in spending decisions.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    42, 900. Idenix Pharmaceuticals/ Merck &Co. Company acquisition. Hepatitis C assets include IDX21437 (p1/2 nucleotide inhibitor) to combine with Merck HCV drugs. ... 75. Orion/ Bayer. Co-development, option to co-promote in Europe. OraQuick HCV rapid

  • Pharma deals during June 2014 Pharma deals during June 2014

    Deal type. Headline ($m). Idenix/. Merck &Co. Samtasvir (NS5A inhibitor) other HCV therapies. ... 2, 500. Alios BioPharma/ Vertex. ALS-2200/ALS-2158 (HCV polymerase inhibitors). Preclinical. June 2012.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Wargaming in HCV

    Wargaming in HCV. The challenge:. Our client had a product ready for launch in the HCV landscape.

  • Infographic: HCV LATAM

    If left untreated HCV becomes a chronic health problem putting a huge strain on national healthcare resources. ... Within Latin America studies suggest that around 4.6 million people are currently infected with chronic HCV.

  • Infographic: HCV EU

    Infographic: HCV EU. Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment. ... Our latest market snapshot offers an introduction to the real world patient data collected

  • News: Therapy Watch HCV expands into 4 additional EU markets

    News: Therapy Watch HCV expands into 4 additional EU markets. The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment ... of HCV has moved on in a short space of time; from

  • Access and elimination: the future of DAAs in hepatitis C

    The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700, 000

More from PMHub
Approximately 11 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics